Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.74 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.74 |
| ▸ | MAOA | P21397 | 1/20 | 0.74 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.64 |
| ▸ | BCHE | P06276 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7403715 | 1.00 | MAOB (0.74) | MAOBSCN9AMAOAHRH3BCHE | |
| SCHEMBL1070615 | 1.00 | MAOB (0.74) | MAOBSCN9AMAOAHRH3BCHE | |
| SCHEMBL7390166 | 0.96 | SCN9A (0.70) | MAOBSCN9AMAOAHRH3BCHE | |
| SCHEMBL7390171 | 0.96 | SCN9A (0.70) | MAOBSCN9AMAOAHRH3BCHE | |
| SCHEMBL23440921 | 0.89 | MAOB (0.67) | MAOBSCN9AMAOAHRH3 | |
| SCHEMBL23440991 | 0.88 | MAOB (0.76) | MAOBSCN9AMAOAHRH3 | |
| SCHEMBL23440948 | 0.88 | MAOB (0.65) | MAOBSCN9AMAOAHRH3 | |
| SCHEMBL1069302 | 0.88 | MAOB (0.76) | MAOBSCN9AMAOAHRH3 | |
| SCHEMBL23440930 | 0.88 | MAOB (0.76) | MAOBSCN9AMAOAHRH3 | |
| SCHEMBL2016084 | 0.88 | MAOB (0.76) | MAOBSCN9AMAOAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102274517-A | Methods for treatment of parkinson's disease | — | 2011-12-14 | — | — | CN | claimed |
| EP-2070526-A1 | \"Methods for treatment of Parkinson's disease\ | Newron Pharmaceuticals S.p.A. (IT) | 2009-06-17 | — | — | EP | claimed |
| US-20070093495-A1 | Methods for treatment of parkinson's disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-04-26 | — | — | US | claimed |
| CN-1771030-A | Methods of treating Parkinson's disease | NEWRON PHARMACEUTICALS INC (IT) | 2006-05-10 | — | — | CN | claimed |
| EP-1613296-A2 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | Newron Pharmaceuticals S.p.A. (IT) | 2006-01-11 | — | — | EP | claimed |
| WO-2004089353-A2 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2004-10-21 | — | — | WO | claimed |
| US-10792257-B2 | Pharmaceutical compositions comprising safinamide | ZAMBON S.P.A. (IT) | 2020-10-06 | — | — | US | disclosed |
| EP-3257842-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | Newron Pharmaceuticals S.p.A. (IT) | 2017-12-20 | — | — | EP | disclosed |
| EP-2229351-B1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARM SPA (IT) | 2017-11-08 | — | — | EP | disclosed |
| US-9492410-B2 | Methods for treatment of Parkinson's disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2016-11-15 | — | — | US | disclosed |
| EP-2474521-B1 | High purity degree 2-[4-(3- and 2-fluorobenzyloxy)benzylamino]propanamides for use as medicaments and pharmaceutical formulations containing them | NEWRON PHARM SPA (IT) | 2016-08-10 | — | — | EP | disclosed |
| US-20150150833-A1 | Methods For Treatment of Parkinson's Disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2015-06-04 | — | — | US | disclosed |
| US-8901176-B2 | Methods for treatment of Parkinson's disease | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2014-12-02 | — | — | US | disclosed |
| WO-2004089353-A2 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2004-10-21 | — | — | WO | disclosed |
| US-5502079-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | FARMITALIA CARLO ERBA S.R.L. (IT) | 1996-03-26 | — | — | US | disclosed |
| US-5391577-A | Active on central nervous system; antiepileptic agents | FARMITALIA CARLO ERBA S R L (IT) | 1995-02-21 | — | — | US | disclosed |
| US-5236957-A | Antiepileptic agents | FARMITALIA CARLO ERBA SRL (IT) | 1993-08-17 | — | — | US | disclosed |
| EP-0426816-A1 | N-PHENYLALKYL SUBSTITUTED $g(a)-AMINO CARBOXAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.r.l. (IT) | 1991-05-15 | — | — | EP | disclosed |
| EP-0400495-A1 | N-phenylalkyl substituted alfa-amino carboxamide derivatives and process for their preparation | FARMITALIA CARLO ERBA S.r.l. (IT) | 1990-12-05 | — | — | EP | disclosed |
| WO-1990014334-A1 | N-PHENYLALKYL SUBSTITUTED α-AMINO CARBOXAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.R.L. (IT) | 1990-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093495-A1 | Methods for treatment of parkinson's disease | MAOB, MAOA, SNCA | MAOB 1/4885SCN9A 2416/4885MAOA 2/4885 |
| US-10792257-B2 | Pharmaceutical compositions comprising safinamide | TAS2R5, TAS2R42, TAS2R45 | MAOB 1088/4885SCN9A 85/4885MAOA 1367/4885 |
| US-20150150833-A1 | Methods For Treatment of Parkinson's Disease | MAOB, MAOA, SNCA | MAOB 1/4885SCN9A 2416/4885MAOA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.